FDA Approves New Painkiller, but Questions Efficacy on Stomach Safety

Strategic Insights -

The US Food and Drug Administration (FDA) has approved Celebrex, a new type of painkiller designed to alleviate arthritis pain while minimizing stomach-plaguing side effects. However, the agency cast doubt on the drug's purported safety benefits, stating that there is insufficient evidence to prove it is easier on patients' stomachs than older competitors. Celebrex, manufactured by G.D. Searle, is the first in a new class of painkillers called "cox-2 inhibitors." The FDA's decision has raised questions about how many arthritis patients will try the new drug and whether they should switch from older painkillers to Celebrex.

Key Takeaways:

  • The FDA has approved Celebrex, a new painkiller, but has not confirmed its stomach-safe benefits as touted by manufacturers.
  • The agency declared that there is no proof that Celebrex is easier on patients' stomachs than older competitors, despite manufacturer G.D. Searle's claims.
  • Celebrex will carry the same warning about side effects as many of today's standard painkillers.
  • Arthritis patients with current stomach problems might consider switching to Celebrex, but healthy patients with no stomach issues should not switch, according to Georgetown University rheumatologist Dr. Stephen Ray Mitchell.
  • Searle expects Celebrex to be available by prescription within six weeks and priced around $2.40 a day, comparable to other prescription painkillers.
  • The FDA's warning may influence the demand for Celebrex and its adoption among arthritis patients.
  • The FDA's decision highlights the tension between regulatory agencies and pharmaceutical companies over the approval of new drugs.

Statistics:

  • 19 million people suffer from arthritis.
  • The new class of painkillers called "cox-2 inhibitors" includes Celebrex as its only approved member.
  • $2.40: The expected daily price for Celebrex, comparable to other prescription painkillers.
  • 6 weeks: The timeframe in which Searle expects Celebrex to be available by prescription.

Sources:

  • The Associated Press Washington (exact date not specified)
  • Dr. Murray Lumpkin, FDA drug chief
  • Dr. Joseph Markenson, Cornell Medical College
  • Dr. Stephen Ray Mitchell, Georgetown University rheumatologist
  • G.D. Searle, manufacturer of Celebrex.